Information for "LongTerm Efficiency Connection between Natalizumab as opposed to Fingolimod in People Together with Remarkably Productive RelapsingRemitting Ms RealWorld Info From a Ms Guide Middle"
From EECH Central
Basic information
Display title | LongTerm Efficiency Connection between Natalizumab as opposed to Fingolimod in People Together with Remarkably Productive RelapsingRemitting Ms RealWorld Info From a Ms Guide Middle |
Default sort key | LongTerm Efficiency Connection between Natalizumab as opposed to Fingolimod in People Together with Remarkably Productive RelapsingRemitting Ms RealWorld Info From a Ms Guide Middle |
Page length (in bytes) | 3,265 |
Page ID | 1287641 |
Page content language | English (en) |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Page protection
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Edit history
Page creator | Pingstorm68 (Talk | contribs) |
Date of page creation | 10:27, 21 March 2024 |
Latest editor | Pingstorm68 (Talk | contribs) |
Date of latest edit | 10:27, 21 March 2024 |
Total number of edits | 1 |
Total number of distinct authors | 1 |
Recent number of edits (within past 90 days) | 1 |
Recent number of distinct authors | 1 |